View Item 

Show simple item record

Association of combined PD- L1 expression and tumour- infiltrating lymphocyte features with survival and treatment outcomes in patients with metastatic melanoma
dc.contributor.authorBence, C.
dc.contributor.authorHofman, V.
dc.contributor.authorChamorey, E.
dc.contributor.authorLong‐mira, E.
dc.contributor.authorLassalle, S.
dc.contributor.authorAlbertini, A.F.
dc.contributor.authorLiolios, I.
dc.contributor.authorZahaf, K.
dc.contributor.authorPicard, A.
dc.contributor.authorMontaudié, H.
dc.contributor.authorLacour, J.P.
dc.contributor.authorPasseron, T.
dc.contributor.authorAndea, A.A.
dc.contributor.authorIlie, M.
dc.contributor.authorHofman, P.
dc.date.accessioned2020-06-03T15:22:43Z
dc.date.availableWITHHELD_12_MONTHS
dc.date.available2020-06-03T15:22:43Z
dc.date.issued2020-05
dc.identifier.citationBence, C.; Hofman, V.; Chamorey, E.; Long‐mira, E. ; Lassalle, S.; Albertini, A.F.; Liolios, I.; Zahaf, K.; Picard, A.; Montaudié, H. ; Lacour, J.P.; Passeron, T.; Andea, A.A.; Ilie, M.; Hofman, P. (2020). "Association of combined PD- L1 expression and tumour- infiltrating lymphocyte features with survival and treatment outcomes in patients with metastatic melanoma." Journal of the European Academy of Dermatology and Venereology (5): 984-994.
dc.identifier.issn0926-9959
dc.identifier.issn1468-3083
dc.identifier.urihttps://hdl.handle.net/2027.42/155478
dc.description.abstractBackgroundRecent advances obtained with immune checkpoint inhibitors (ICIs) targeting the programmed cell death- 1 (PD- 1) protein have significantly improved the outcome of patients with metastatic melanoma. The PD- L1 expression in tumour cells as detected by immunohistochemistry is a predictive biomarker in some solid tumours, but appears insufficient as prognostic or predictive factor of response to ICIs in metastatic melanomas.ObjectivesWe investigated whether the presence and the features of pretreatment CD8+tumour- infiltrating T lymphocytes (TILs) could be a complementary prognostic or predictive biomarker in patients with metastatic melanoma.MethodsIn this retrospective study, we evaluated the association of PD- L1 expression - ¥5% of tumour cells combined with TIL features (CD8, CD28, Ki67) with the overall survival (OS) among 51 patients treated with ICIs and 54 patients treated with other treatment options (non- ICIs).ResultsPD- L1 positivity was observed in 33% and 39% of primary melanomas and matched metastases, respectively, with, however, poor concordance between the primary and the matched metastatic site (κ = 0.283). No significant association was noted between PD- L1 expression and CD8+TIL profile analysed as single markers and OS or response to immunotherapy. Instead, their combined analysis in primary melanoma samples showed that the PD- L1- /CD8+status was significantly associated with prolonged OS in the whole population (P = 0.04) and in the subgroup treated with non- ICIs (P = 0.009). Conversely, the PD- L1+/CD8+ status was a good prognostic factor in patients treated with ICIs (P = 0.022), whereas was significantly associated with poor prognosis in patients treated with non- ICIs (P = 0.014). While the expression of CD28 was not related to outcome, the Ki67 expression was significantly associated with poor OS in the subgroup CD8+TIL+/PD- L1- (P = 0.02).ConclusionsThe pretreatment combination of PD- L1 expression with the level of CD8+TILs could better assess OS and predict therapeutic response of patients with metastatic melanoma treated by either immunotherapy or other treatment regimens.
dc.publisherWiley Periodicals, Inc.
dc.titleAssociation of combined PD- L1 expression and tumour- infiltrating lymphocyte features with survival and treatment outcomes in patients with metastatic melanoma
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelDermatology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/155478/1/jdv16016_am.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/155478/2/jdv16016.pdf
dc.identifier.doi10.1111/jdv.16016
dc.identifier.sourceJournal of the European Academy of Dermatology and Venereology
dc.identifier.citedreferenceLarkin J, Chiarion- Sileni V, Gonzalez R et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015; 373: 23 - 34.
dc.identifier.citedreferenceHerbst RS, Soria JC, Kowanetz M et al. Predictive correlates of response to the anti- PD- L1 antibody MPDL3280A in cancer patients. Nature 2014; 515: 563 - 567.
dc.identifier.citedreferenceTumeh PC, Harview CL, Yearley JH et al. PD- 1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014; 515: 568 - 571.
dc.identifier.citedreferenceTeng MW, Ngiow SF, Ribas A et al. Classifying cancers based on T- cell infiltration and PD- L1. Cancer Res 2015; 75: 2139 - 2145.
dc.identifier.citedreferenceTaube JM, Anders RA, Young GD et al. Colocalization of inflammatory response with B7- h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 2012; 4: 127ra37.
dc.identifier.citedreferenceMadonna G, Ballesteros- Merino C, Feng Z et al. PD- L1 expression with immune- infiltrate evaluation and outcome prediction in melanoma patients treated with ipilimumab. Oncoimmunology 2018; 7: e1405206.
dc.identifier.citedreferenceHui E, Cheung J, Zhu J et al. T cell costimulatory receptor CD28 is a primary target for PD- 1- mediated inhibition. Science 2017; 355: 1428 - 1433.
dc.identifier.citedreferenceKamphorst AO, Wieland A, Nasti T et al. Rescue of exhausted CD8 T cells by PD- 1- targeted therapies is CD28- dependent. Science 2017; 355: 1423 - 1427.
dc.identifier.citedreferenceWolchok JD, Kluger H, Callahan MK et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013; 369: 122 - 133.
dc.identifier.citedreferenceWeber JS, D’Angelo SP, Minor D et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti- CTLA- 4 treatment (CheckMate 037): a randomised, controlled, open- label, phase 3 trial. Lancet Oncol 2015; 16: 375 - 384.
dc.identifier.citedreferenceHendry S, Salgado R, Gevaert T et al. Assessing tumor- infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the International Immuno- Oncology Biomarkers Working Group: part 2: TILs in melanoma, gastrointestinal tract carcinomas, non- small cell lung carcinoma and mesothelioma, endometrial and ovarian carcinomas, squamous cell carcinoma of the head and neck, genitourinary carcinomas, and primary brain tumors. Adv Anat Pathol 2017; 24: 311 - 335.
dc.identifier.citedreferenceAzimi F, Scolyer RA, Rumcheva P et al. Tumor- infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. J Clin Oncol 2012; 30: 2678 - 2683.
dc.identifier.citedreferenceBrambilla E, Le Teuff G,jdv Marguet S et al. Prognostic effect of tumor lymphocytic infiltration in resectable non- small- cell lung cancer. J Clin Oncol 2016; 34: 1223 - 1230.
dc.identifier.citedreferenceIlie MI, Lassalle S, Long- Mira E et al. Diagnostic value of immunohistochemistry for the detection of the BRAF(V600E) mutation in papillary thyroid carcinoma: comparative analysis with three DNA- based assays. Thyroid 2014; 24: 858 - 866.
dc.identifier.citedreferenceRibas A, Hamid O, Daud A et al. Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA 2016; 315: 1600 - 1609.
dc.identifier.citedreferenceTray N, Weber JS, Adams S. Predictive biomarkers for checkpoint immunotherapy: current status and challenges for clinical application. Cancer Immunol Res 2018; 6: 1122 - 1128.
dc.identifier.citedreferenceLawrence MS, Stojanov P, Polak P et al. Mutational heterogeneity in cancer and the search for new cancer- associated genes. Nature 2013; 499: 214 - 218.
dc.identifier.citedreferenceBerry S, Taube JM. Innate vs. adaptive: PD- L1- mediated immune resistance by melanoma. Oncoimmunology 2015; 4: e1029704.
dc.identifier.citedreferenceMadore J, Vilain RE, Menzies AM et al. PD- L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti- PD- 1/PD- L1 clinical trials. Pigment Cell Melanoma Res 2015; 28: 245 - 253.
dc.identifier.citedreferenceYang S, Leone DA, Biswas A et al. Concordance of somatic mutation profiles (BRAF, NRAS, and TERT) and tumoral PD- L1 in matched primary cutaneous and metastatic melanoma samples. Hum Pathol 2018; 82: 206 - 214.
dc.identifier.citedreferenceWong PF, Wei W, Smithy JW et al. Multiplex quantitative analysis of tumor- infiltrating lymphocytes and immunotherapy outcome in metastatic melanoma. Clin Cancer Res 2019; 25: 2442 - 2449.
dc.identifier.citedreferenceSteiniche T, Vestergaard Danielsen A, Wang Z et al. PD- L1 expression and survival among melanoma patients treated with standard immunotherapy or chemotherapy. J Eur Acad Dermatol Venereol 2017; 31: e319 - e321.
dc.identifier.citedreferenceDaud AI, Wolchok JD, Robert C et al. Programmed death- ligand 1 expression and response to the anti- programmed death 1 antibody pembrolizumab in melanoma. J Clin Oncol 2016; 34: 4102 - 4109.
dc.identifier.citedreferenceBurton AL, Roach BA, Mays MP et al. Prognostic significance of tumor infiltrating lymphocytes in melanoma. Am Surg 2011; 77: 188 - 192.
dc.identifier.citedreferenceLee N, Zakka LR, Mihm MC Jr et al. Tumour- infiltrating lymphocytes in melanoma prognosis and cancer immunotherapy. Pathology 2016; 48: 177 - 187.
dc.identifier.citedreferenceClemente CG, Mihm MC Jr, Bufalino R et al. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996; 77: 1303 - 1310.
dc.identifier.citedreferenceRodic N, Anders RA, Eshleman JR et al. PD- L1 expression in melanocytic lesions does not correlate with the BRAF V600E mutation. Cancer Immunol Res 2015; 3: 110 - 115.
dc.identifier.citedreferenceFrydenlund N, Leone D, Yang S et al. Tumoral PD- L1 expression in desmoplastic melanoma is associated with depth of invasion, tumor- infiltrating CD8 cytotoxic lymphocytes and the mixed cytomorphological variant. Mod Pathol 2017; 30: 357 - 369.
dc.identifier.citedreferenceChae YK, Arya A, Iams W et al. Current landscape and future of dual anti- CTLA4 and PD- 1/PD- L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non- small cell lung cancer (NSCLC). J Immunother Cancer 2018; 6: 39.
dc.identifier.citedreferenceBray F, Ferlay J, Soerjomataram I et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394 - 424.
dc.identifier.citedreferenceGershenwald JE, Scolyer RA, Hess KR et al. Melanoma staging: evidence- based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 2017; 67: 472 - 492.
dc.identifier.citedreferenceTopalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti- PD- 1 antibody in cancer. N Engl J Med 2012; 366: 2443 - 2454.
dc.identifier.citedreferenceRobert C, Long GV, Brady B et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015; 372: 320 - 330.
dc.identifier.citedreferenceWolchok JD, Chiarion- Sileni V, Gonzalez R et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 2017; 377: 1345 - 1356.
dc.identifier.citedreferenceGandini S, Massi D, Mandala M. PD- L1 expression in cancer patients receiving anti PD- 1/PD- L1 antibodies: a systematic review and meta- analysis. Crit Rev Oncol Hematol 2016; 100: 88 - 98.
dc.identifier.citedreferenceTaube JM, Klein A, Brahmer JR et al. Association of PD- 1, PD- 1 ligands, and other features of the tumor immune microenvironment with response to anti- PD- 1 therapy. Clin Cancer Res 2014; 20: 5064 - 5074.
dc.identifier.citedreferenceMassi D, Brusa D, Merelli B et al. PD- L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristics. Ann Oncol 2014; 25: 2433 - 2442.
dc.identifier.citedreferenceWang Q, Liu F, Liu L. Prognostic significance of PD- L1 in solid tumor: an updated meta- analysis. Medicine (Baltimore) 2017; 96: e6369.
dc.identifier.citedreferenceHino R, Kabashima K, Kato Y et al. Tumor cell expression of programmed cell death- 1 ligand 1 is a prognostic factor for malignant melanoma. Cancer 2010; 116: 1757 - 1766.
dc.identifier.citedreferenceKluger HM, Zito CR, Barr ML et al. Characterization of PD- L1 expression and associated T- cell infiltrates in metastatic melanoma samples from variable anatomic sites. Clin Cancer Res 2015; 21: 3052 - 3060.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
jdv16016_am.pdf
Size:
341.6KB
Format:
PDF
View/Open
Name:
jdv16016.pdf
Size:
1.550MB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.